Profusa Soars 69.39% on Debt Restructuring, Leadership Shakeup

On August 26, 2025, Profusa's stock surged by 69.39% in pre-market trading, marking a significant rise that caught the attention of investors and analysts alike.

Profusa recently amended its purchase agreement and note terms for convertible debt tranches. This restructuring involves issuing convertible promissory notes in four tranches, which is expected to provide the company with greater financial flexibility and support its ongoing operations and growth initiatives.

Additionally, Profusa has made strategic appointments to its leadership team. The company welcomed Peter O’Rourke, the former Acting U.S. Veterans Affairs Secretary, as its Lead Independent Director. This move is seen as a significant step in strengthening Profusa's governance and strategic direction. Furthermore, Fred Knechtel, a seasoned finance executive, has been appointed as the new Chief Financial Officer, bringing valuable expertise to the company's financial management.

These developments, along with Profusa's ongoing efforts to expand its biosensor platform globally, have contributed to the positive market sentiment surrounding the company. Investors are optimistic about Profusa's potential for growth and its ability to capitalize on emerging opportunities in the biosensor market.